Colon and Rectal Cancer Drugs Market Size Share - Emerging Evolution, Advancement, Industry Trends and Forecast 2018 - 2026
The report classifies the global Colon and Rectal Cancer Drugs Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.
(EMAILWIRE.COM, September 17, 2018 ) Colon and rectal cancer are often grouped together, as they have many common features. Rate of colorectal cancer is increasing among the millennials in the U.S. The American Cancer Society (ACS) estimates that there will be around 97,220 new cases of colon cancer and around 43,030 new cases of rectal cancer registered in the U.S. in 2018. Moreover, owing to increasing risk of colorectal cancer, in May 2018, ACS updated their guidelines for colorectal cancer screenings and recommended to start colorectal cancer screening at the age of 45 rather than at the age of 50.
Increasing incidence and prevalence of colon and rectal cancer, worldwide and increasing research and development studies for colorectal cancer treatment is expected to drive growth of colon and rectal cancer market in the near future. For instance, according to February 2018 data findings of the American Cancer Society (ACS), colorectal cancer is the third most common cancer diagnosed in both men and women in the U.S.
Request a sample copy : https://www.coherentmarketinsights.com/insight/request-sample/2019
By Drug Type:
Single Drug
Colon Cancer
Cetuximab
Bevacizumab
Avastin
Capecitabine
Nivolumab
Panitumumab
Oxaliplatin
Others
Rectal Cancer
Avastin
Capecitabine
Erbitux
Cyramza
Irinotecan Hydrochloride
Nivolumab
Others
Combination Drug
Colon Cancer
CAPOX
FOLFOX
FOLFIRI
FOLFIRI-CETUXIMAB
XELIRI
Others
Rectal Cancer
FU-LV
CAPOX
FOLFIRI-BEVACIZUMAB
XELOX
XELIRI
Others
By Distribution Channels:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East
Africa
Increasing number of research and development (R&D) studies by government and private healthcare organizations is also fueling growth of colon and rectal cancer drugs market. For instance, the American Cancer Society (ACS) spend US$ 54 million on colon and rectal cancer research involving 92 research grants, till March 2018.
Lack of development in the neoadjuvant/adjuvant pipeline agents for the treatment of high risk colorectal cancer resulted in slower growth of colon and rectal cancer drugs market. For instance, according to the data published in the National Center for Biotechnology Information (NCBI) in April 2016, there is lack of clinical trials of systemic adjuvant, neoadjuvant, and perioperative chemotherapy for the treatment of colorectal liver metastases (CRLM). These offers lucrative opportunity for the key players to develop new treatment therapy using neoadjuvant agents for resected patients.
Furthermore, improper reimbursement policies for colorectal cancer treatment in certain countries hampers growth of the global colon and rectal cancer drugs market. For instance, according to the comparison study published in the American Society of Clinical Oncology (ASCO) 2018 meeting, treatment cost of metastatic colorectal cancer in Western Washington (U.S.) is higher than the province of British Columbia (BC) in Canada, with no significant difference in the outcome.
Colon and Rectal Cancer Drugs Market – Regional Analysis
On the basis of region, the global colon and rectal cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in the colon and rectal cancer drugs market, followed by Europe. This is owing to increasing incidence rate of colorectal cancer in these regions. According to the World Cancer Research Fund International, in 2012, Republic of Korea had the highest rate of colorectal cancer, followed by Slovakia and Hungary. Furthermore, since few years, large number of colorectal cancer incidences were registered in Oceania and Europe region, while it shows lowest incidence rates in Africa and Asia region.
Colon and Rectal Cancer Drugs Market – Competitive Analysis
Some of the key players operating in the global colon and rectal cancer drugs market include Amgen Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Company, Merck KGaA, Novartis International AG, Sirtex Medical Limited, Sanofi S.A. Sorrento Therapeutics, and Takeda Pharmaceutical Company Ltd. Key players in the market are involved in research and development activities to conduct clinical trial studies and to gain regulatory approval. For instance, in March 2018, Daiichi Sankyo initiated phase II study of DS-8201 in patients with HER2-expressing advanced colorectal cancer. Currently, there is no HER2 –targeting therapy approved for patients suffering from HER2- expressing colorectal cancer. Initiation of HER2 phase clinical trial study by Daiichi Sankyo for colorectal cancer treatment will help to improve the outcomes in colorectal cancer patients. In March 2018, FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, which is administrated intravenously for the treatment of adult and pediatric (12 years and older) patients who suffer from microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.
Else place an Inquire before Purchase “Colon and Rectal Cancer Drugs Market Size, Status and Forecast 2026 : https://www.coherentmarketinsights.com/insight/talk-to-analyst/2019
Increasing incidence and prevalence of colon and rectal cancer, worldwide and increasing research and development studies for colorectal cancer treatment is expected to drive growth of colon and rectal cancer market in the near future. For instance, according to February 2018 data findings of the American Cancer Society (ACS), colorectal cancer is the third most common cancer diagnosed in both men and women in the U.S.
Request a sample copy : https://www.coherentmarketinsights.com/insight/request-sample/2019
By Drug Type:
Single Drug
Colon Cancer
Cetuximab
Bevacizumab
Avastin
Capecitabine
Nivolumab
Panitumumab
Oxaliplatin
Others
Rectal Cancer
Avastin
Capecitabine
Erbitux
Cyramza
Irinotecan Hydrochloride
Nivolumab
Others
Combination Drug
Colon Cancer
CAPOX
FOLFOX
FOLFIRI
FOLFIRI-CETUXIMAB
XELIRI
Others
Rectal Cancer
FU-LV
CAPOX
FOLFIRI-BEVACIZUMAB
XELOX
XELIRI
Others
By Distribution Channels:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East
Africa
Increasing number of research and development (R&D) studies by government and private healthcare organizations is also fueling growth of colon and rectal cancer drugs market. For instance, the American Cancer Society (ACS) spend US$ 54 million on colon and rectal cancer research involving 92 research grants, till March 2018.
Lack of development in the neoadjuvant/adjuvant pipeline agents for the treatment of high risk colorectal cancer resulted in slower growth of colon and rectal cancer drugs market. For instance, according to the data published in the National Center for Biotechnology Information (NCBI) in April 2016, there is lack of clinical trials of systemic adjuvant, neoadjuvant, and perioperative chemotherapy for the treatment of colorectal liver metastases (CRLM). These offers lucrative opportunity for the key players to develop new treatment therapy using neoadjuvant agents for resected patients.
Furthermore, improper reimbursement policies for colorectal cancer treatment in certain countries hampers growth of the global colon and rectal cancer drugs market. For instance, according to the comparison study published in the American Society of Clinical Oncology (ASCO) 2018 meeting, treatment cost of metastatic colorectal cancer in Western Washington (U.S.) is higher than the province of British Columbia (BC) in Canada, with no significant difference in the outcome.
Colon and Rectal Cancer Drugs Market – Regional Analysis
On the basis of region, the global colon and rectal cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in the colon and rectal cancer drugs market, followed by Europe. This is owing to increasing incidence rate of colorectal cancer in these regions. According to the World Cancer Research Fund International, in 2012, Republic of Korea had the highest rate of colorectal cancer, followed by Slovakia and Hungary. Furthermore, since few years, large number of colorectal cancer incidences were registered in Oceania and Europe region, while it shows lowest incidence rates in Africa and Asia region.
Colon and Rectal Cancer Drugs Market – Competitive Analysis
Some of the key players operating in the global colon and rectal cancer drugs market include Amgen Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Company, Merck KGaA, Novartis International AG, Sirtex Medical Limited, Sanofi S.A. Sorrento Therapeutics, and Takeda Pharmaceutical Company Ltd. Key players in the market are involved in research and development activities to conduct clinical trial studies and to gain regulatory approval. For instance, in March 2018, Daiichi Sankyo initiated phase II study of DS-8201 in patients with HER2-expressing advanced colorectal cancer. Currently, there is no HER2 –targeting therapy approved for patients suffering from HER2- expressing colorectal cancer. Initiation of HER2 phase clinical trial study by Daiichi Sankyo for colorectal cancer treatment will help to improve the outcomes in colorectal cancer patients. In March 2018, FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, which is administrated intravenously for the treatment of adult and pediatric (12 years and older) patients who suffer from microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.
Else place an Inquire before Purchase “Colon and Rectal Cancer Drugs Market Size, Status and Forecast 2026 : https://www.coherentmarketinsights.com/insight/talk-to-analyst/2019
Contact Information:
Coherent Market Insights
Mr. Shah
Tel: +1 2067016702
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Coherent Market Insights
Mr. Shah
Tel: +1 2067016702
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results